Takeda Pharmaceutical Morgan Bond

TKPHF Stock  USD 25.83  0.26  1.00%   
Takeda Pharmaceutical holds a debt-to-equity ratio of 0.809. . Takeda Pharmaceutical's financial risk is the risk to Takeda Pharmaceutical stockholders that is caused by an increase in debt.
76.1%

Asset vs Debt

55.3%

Equity vs Debt

Takeda Pharmaceutical's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Takeda Pharmaceutical's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Takeda Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Takeda Pharmaceutical's stakeholders.
For most companies, including Takeda Pharmaceutical, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Takeda Pharmaceutical Co, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Takeda Pharmaceutical's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
  
Check out the analysis of Takeda Pharmaceutical Fundamentals Over Time.
View Bond Profile
Given the importance of Takeda Pharmaceutical's capital structure, the first step in the capital decision process is for the management of Takeda Pharmaceutical to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Takeda Pharmaceutical Co to issue bonds at a reasonable cost.
Popular NameTakeda Pharmaceutical Morgan Stanley 3591
Equity ISIN CodeJP3463000004
Bond Issue ISIN CodeUS61744YAK47
S&P Rating
Others
Maturity Date22nd of July 2028
Issuance Date24th of July 2017
Coupon3.591 %
View All Takeda Pharmaceutical Outstanding Bonds

Takeda Pharmaceutical Outstanding Bond Obligations

Understaning Takeda Pharmaceutical Use of Financial Leverage

Takeda Pharmaceutical's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Takeda Pharmaceutical's total debt position, including all outstanding debt obligations, and compares it with Takeda Pharmaceutical's equity. Financial leverage can amplify the potential profits to Takeda Pharmaceutical's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Takeda Pharmaceutical is unable to cover its debt costs.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutica operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 47347 people.
Please read more on our technical analysis page.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Takeda Pink Sheet

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out the analysis of Takeda Pharmaceutical Fundamentals Over Time.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.